References
- Ghazalpour A, Bennett B, Petyuk VA, Orozco L, Hagopian R, Mungrue IN, et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 2011; 7:e1001393; http://dx.doi.org/10.1371/journal.pgen.1001393; PMID: 21695224
- Mata J, Marguerat S, Bähler J. Post-transcriptional control of gene expression: a genome-wide perspective. Trends Biochem Sci 2005; 30:506 - 14; http://dx.doi.org/10.1016/j.tibs.2005.07.005; PMID: 16054366
- Glisovic T, Bachorik JL, Yong J, Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett 2008; 582:1977 - 86; http://dx.doi.org/10.1016/j.febslet.2008.03.004; PMID: 18342629
- Jha S, Komar AA. Birth, life and death of nascent polypeptide chains. Biotechnol J 2011; 6:623 - 40; http://dx.doi.org/10.1002/biot.201000327; PMID: 21538896
- Safina A, Garcia H, Commane M, Guryanova O, Degan S, Kolesnikova K, et al. Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells. Cell Cycle 2013; 12; PMID: 23839038
- Saunders A, Werner J, Andrulis ED, Nakayama T, Hirose S, Reinberg D, et al. Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo. Science 2003; 301:1094 - 6; http://dx.doi.org/10.1126/science.1085712; PMID: 12934007
- Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, et al. FACT is an “accelerator” of tumor transformation and potential marker and target of aggressive cancers. Cell Reports 2013; http://dx.doi.org/10.1016/j.celrep.2013.06.013; PMID: 23831030
- Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, et al. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med 2011; 3:95ra74; http://dx.doi.org/10.1126/scitranslmed.3002530; PMID: 21832239